经股动脉PCI术中比伐芦定与普通肝素的临床比较  

Comparison of heparin versus bivalirudin among patients underwent PCI via transfemoral pathway

作　　者：闫贤良[1] 程宇彤[1] 王苏[1] 林运[1] 张京梅[1] 李志忠[1] 

机构地区：[1]首都医科大学附属北京安贞医院心内科十五病房,北京100029

出　　处：《中国循证心血管医学杂志》2017年第9期1045-1047,共3页Chinese Journal of Evidence-Based Cardiovascular Medicine

基　　金：基金名称:心血管疾病精准医学北京实验室(PXM2016-014226-000037)

摘　　要：目的评价比伐芦定在经股动脉途径经皮冠状动脉介入术(PCI)术中的安全性与有效性。方法连续入选2016年3月~2017年3月于北京安贞医院行经股动脉途径PCI的冠心病患者63例,根据术中抗凝药物的使用情况分为2组:比伐芦定组(n=30)和普通肝素组(n=33)。观察指标为PCI围术期出血和主要不良心血管事件(MACE)发生率。结果比伐芦定组和普通肝素组的30 d MACE发生率比较(6.7%vs.6.1%)差异无统计学意义(P>0.05)。而出血事件发生率均低于普通肝素组,差异有统计学意义(P<0.05)。结论比伐芦定可安全有效的应用于经股动脉途径行PCI的患者。Objective To evaluate the efficacy and safety of bivalirudin among patients underwent percutaneous coronary intervention （PCI） via transfemoral pathway. Methods 63 coronary heart disease （CHD） patients who underwent PCI via transfemoral pathway from March 2015 to March 2016 in Anzhen hospital were enrolled. Based on the anticoagulant therapy during perioperative period, the patients were divided into bivalirudin group （n=30） and heparin group （n=33）. The incidences of peri-operative bleeding and major adverse cardiac events （MACE） were compared between two groups. Results The incidence of MACE in bivalirudin group was 6.7%, which was higher than heparin group （6.1%）, but there is no significant difference between two groups. The bleeding rate in bivalirudin group was lower than heparin group. Conclusion Bivalirudin is effective and safe in CHD patients underwent PCI via transfemoral pathway.

关 键 词：比伐芦定 肝素 股动脉途径 经皮冠状动脉介入术 

分 类 号：R816.2[医药卫生—放射医学]